OncoMatch/Clinical Trials/NCT03935893
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Is NCT03935893 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tumor Infiltrating Lymphocytes (TIL) and Fludarabine + Cyclophosphamide combination for gastric cancer.
Treatment: Tumor Infiltrating Lymphocytes (TIL) · Fludarabine + Cyclophosphamide combination — This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic cancer associated with one of the following cancer types: 1.) gastric/esophagogastric, 2.) colorectal, 3.) pancreatic, 4.) sarcoma, 5.) mesothelioma, 6.) neuroendocrine, 7.) squamous cell cancer, 8.) Merkle cell, 9.) mismatch repair deficient and/or microsatellite unstable cancers, and 10.) patients who have exhausted conventional systemic therapy options by using the objective response rate (ORR).
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Colorectal Cancer
Pancreatic Cancer
Sarcoma
Mesothelioma
Neuroendocrine Tumor
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — first-line for metastatic disease
must have previously received approved first-line systemic therapies if they are eligible to receive these treatments
Lab requirements
Blood counts
Absolute neutrophil count greater than 1000/mm3 without the support of filgrastim; WBC ≥ 3000/mm3; Platelet count ≥ 100,000/mm3; Hemoglobin > 8.0 g/dl
Kidney function
Serum creatinine ≤ to 1.6 mg/dl
Liver function
Serum ALT/AST ≤ to 3.5 times the upper limit of normal; Total bilirubin ≤ to 2.0 mg/dl, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl
Cardiac function
Documented LVEF of less than or equal to 45%; testing required in patients with age > 65 years, clinically significant arrhythmias, or history of ischemic heart disease/chest pain
Serum ALT/AST ≤ to 3.5 times the upper limit of normal Serum creatinine ≤ to 1.6 mg/dl; Total bilirubin ≤ to 2.0 mg/dl, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl; Documented LVEF of less than or equal to 45%; note: testing is required in patients with: Age > 65 years' old; Clinically significant atrial and or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second- or third-degree heart block or have a history of ischemic heart disease, chest pain.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UPMC Hillman Cancer Center · Pittsburgh, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify